ScarEarly Phase 1NCT00700791
Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars
A Early Phase 1 study testing Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) in people with Scar, run by Chandan K Sen at 2 sites in United States.
Trial summary
The overall goal of this study is to determine the efficacy of tocotrienol (TCT), a natural form of vitamin E, in preventing or reducing scar formation in human skin wounds as well as the basal levels of TCT in normal human skin and adipose tissue. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Scar
- What is being tested?
- Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT)
- Type of treatment
- Pill or oral medicine, Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 168 participants
- Where
- 2 sitesUnited States
- Study dates
- Jul 2008to Jul 2018
- Phase
- Early Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- 18 years of age or older.
- Non- smoker
- No current medications that alter liver metabolism (e.g., Phenobarbital, HmG co-A inhibitors, etc.)
- Non- pregnant or non-breastfeeding
- No current use of dietary supplements containing vitamin-E
- Not actively abusing drugs or alcohol
Who cannot join
- Under 18 years of age
- Prisoners
- Current smoker
- Pregnant or breastfeeding
- HIV diagnosis
- Viral hepatitis diagnosis
Show all 9Show fewer
- Immunosuppressive therapy
- Actively abusing drugs or alcohol
- Current use of dietary supplements containing vitamin-E
Trial locations and contacts
2 sites in 1 country.
United States2 sites
OSU Plastic Surgery - Knightsbridge
Columbus, Ohio, 43214
The Ohio State University
Columbus, Ohio, 43221
About this study
The overall goal of this study is to determine the efficacy of tocotrienol (TCT), a natural form of vitamin E, in preventing or reducing scar formation in human skin wounds as well as the basal levels of TCT in normal human skin and adipose tissue.
Read the detailed description
Scar formation is the physiological and inevitable end point of mammalian wound healing and there is substantial evidence that inflammation is an essential prerequisite for scarring. Although scar tissue restores the normal skin barrier, the new tissue is inferior in structural, aesthetic, and functional respects. The mammalian wound healing response may have originated during the time of high susceptibility to infection. Therefore, we may have developed speed optimized wound healing where a multiple redundant compensating rapid inflammatory response allows the wound to heal quickly without infection. The scar is then the price mammals have to pay for evolutionary survival after being wounded.
Tocotrienol may be an effective tool to prevent or reduce normal, hypertrophic, or keloid scarring by mediating the inflammatory response. Tocotrienol is a safe and convenient treatment that could be used by mouth or topically. There has never been a study on the effectiveness of tocotrienol in preventing or reducing scar formation.
- Conditions
- Scar
- Being tested
- Natural Vitamin E Tocotrienol supplement (TCT), Natural Vitamin E Tocotrienol Cream (TCT), Placebo, Placebo Cream
- Keywords
- Single and bilateral body contouring surgical sites.
- Medical subject headings
- Cicatrix
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Natural Vitamin E Tocotrienol supplement (TCT)Dietary supplement
Also called Oral TCT
Oral Vitamin E Tocotrienol Supplement (TCT)
Natural Vitamin E Tocotrienol Cream (TCT)Device
Also called Topical TCT
Natural Vitamin E Tocotrienol(TCT)Topical Cream
PlaceboOther
Oral Placebo
Placebo CreamOther
Topical Placebo Cream
| Study group | Role | What they receive |
|---|---|---|
| Group I Single Site Randomization | Placebo comparator | Patients with 1 surgical scar will be given both oral placebo and topical cream placebo Receives: Other: Placebo; Other: Placebo Cream |
| Group II Single Site Randomization | Active comparator | Single surgical site will be given oral placebo and topical TCT Receives: Device: Natural Vitamin E Tocotrienol Cream (TCT); Other: Placebo |
| Group III Single Site Randomization | Active comparator | Patients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream Receives: Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT); Other: Placebo Cream |
| Group IV Single Site Randomization | Active comparator | Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT). Receives: Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT); Device: Natural Vitamin E Tocotrienol Cream (TCT) |
| Group I: Bilateral Site Randomization | Placebo comparator | Patients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site. Receives: Other: Placebo; Other: Placebo Cream |
| Group II: Bilateral Site Randomization | Active comparator | Patients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites. Receives: Device: Natural Vitamin E Tocotrienol Cream (TCT); Other: Placebo |
| Group III: Bilateral Site Randomization | Active comparator | Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site. Receives: Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT); Other: Placebo Cream |
| Group IV: Bilateral Site Randomization | Active comparator | Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site. Receives: Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT); Device: Natural Vitamin E Tocotrienol Cream (TCT) |
| Normal Skin and Adipost Tissue Group | No intervention | Normal human skin and adipose tissue will be collected |
What is being measured
The primary outcome is the main question the study is designed to answer.
1.To determine the efficacy of TCT in improving the appearance of post-surgical scars following oral supplementation 2.To determine the efficacy of TCT in improving the appearance of post-surgical scars following topical application
Measured: 4 weeks prior to surgery and 12 weeks post surgery.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Jun 2008 (estimated)
- Study startJul 2008
- Primary completionJul 2018
- Study completionJul 2018
Why it stopped: The PI moved to another Institution
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ScarStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 168 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chandan K Sen
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Chandan K Sen, Ohio State University
- Investigators
- Chandan K Sen, PhD, Principal investigator, Ohio State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00700791
- Sponsor's protocol ID
- 2008H0001
- Status last verified
- Nov 2021
- First submitted
- 17 Jun 2008
- Last updated
- 18 Nov 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy of Natural Vitamin E Tocotrienol on the Treatment of Surgical Scars
- ClinicalTrials.gov ID
- NCT00700791
- Acronym / sponsor ID
- 2008H0001
- Conditions
- Scar
- Keywords
- Single and bilateral body contouring surgical sites.
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: The PI moved to another Institution
- Enrolment
- 168 participants (estimated)
- Lead sponsor
- Chandan K SenUniversity, hospital or other
- Study start
- Jul 2008
- Primary completion
- Jul 2018 (actual)
- Study completion
- Jul 2018 (actual)
- First posted
- 19 Jun 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall goal of this study is to determine the efficacy of tocotrienol (TCT), a natural form of vitamin E, in preventing or reducing scar formation in human skin wounds as well as the basal levels of TCT in normal human skin and adipose tissue.
Detailed description
Scar formation is the physiological and inevitable end point of mammalian wound healing and there is substantial evidence that inflammation is an essential prerequisite for scarring. Although scar tissue restores the normal skin barrier, the new tissue is inferior in structural, aesthetic, and functional respects. The mammalian wound healing response may have originated during the time of high susceptibility to infection. Therefore, we may have developed speed optimized wound healing where a multiple redundant compensating rapid inflammatory response allows the wound to heal quickly without infection. The scar is then the price mammals have to pay for evolutionary survival after being wounded.
Tocotrienol may be an effective tool to prevent or reduce normal, hypertrophic, or keloid scarring by mediating the inflammatory response. Tocotrienol is a safe and convenient treatment that could be used by mouth or topically. There has never been a study on the effectiveness of tocotrienol in preventing or reducing scar formation.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 9
| Arm | Type | Receives |
|---|---|---|
| Group I Single Site Randomization | Placebo comparator | Other: Placebo, Other: Placebo CreamPatients with 1 surgical scar will be given both oral placebo and topical cream placebo |
| Group II Single Site Randomization | Active comparator | Device: Natural Vitamin E Tocotrienol Cream (TCT), Other: PlaceboSingle surgical site will be given oral placebo and topical TCT |
| Group III Single Site Randomization | Active comparator | Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT), Other: Placebo CreamPatients with 1 surgical scar will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream |
| Group IV Single Site Randomization | Active comparator | Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT), Device: Natural Vitamin E Tocotrienol Cream (TCT)Patients with 1 surgical scar will be given both Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT). |
| Group I: Bilateral Site Randomization | Placebo comparator | Other: Placebo, Other: Placebo CreamPatients with bilateral surgical scars will be given both oral placebo and topical cream placebo on one surgical site. |
| Group II: Bilateral Site Randomization | Active comparator | Device: Natural Vitamin E Tocotrienol Cream (TCT), Other: PlaceboPatients with bilateral surgical scars will be given oral placebo and Natural Vitamin E Tocotrienol Cream (TCT) to one of the surgical sites. |
| Group III: Bilateral Site Randomization | Active comparator | Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT), Other: Placebo CreamPatients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and topical placebo cream on one surgical site. |
| Group IV: Bilateral Site Randomization | Active comparator | Dietary Supplement: Natural Vitamin E Tocotrienol supplement (TCT), Device: Natural Vitamin E Tocotrienol Cream (TCT)Patients with bilateral surgical scars will be given Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) on one surgical site. |
| Normal Skin and Adipost Tissue Group | No intervention | –Normal human skin and adipose tissue will be collected |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- 18 years of age or older.
- Non- smoker
- No current medications that alter liver metabolism (e.g., Phenobarbital, HmG co-A inhibitors, etc.)
- Non- pregnant or non-breastfeeding
- No current use of dietary supplements containing vitamin-E
Key exclusion criteria (9 listed)
- Under 18 years of age
- Prisoners
- Current smoker
- Pregnant or breastfeeding
- HIV diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Natural Vitamin E Tocotrienol supplement (TCT)Also: Oral TCTOral Vitamin E Tocotrienol Supplement (TCT) | Dietary supplement | Group III Single Site Randomization, Group III: Bilateral Site Randomization, Group IV Single Site Randomization, Group IV: Bilateral Site Randomization |
| Natural Vitamin E Tocotrienol Cream (TCT)Also: Topical TCTNatural Vitamin E Tocotrienol(TCT)Topical Cream | Device | Group II Single Site Randomization, Group II: Bilateral Site Randomization, Group IV Single Site Randomization, Group IV: Bilateral Site Randomization |
| PlaceboOral Placebo | Other | Group I Single Site Randomization, Group I: Bilateral Site Randomization, Group II Single Site Randomization, Group II: Bilateral Site Randomization |
| Placebo CreamTopical Placebo Cream | Other | Group I Single Site Randomization, Group I: Bilateral Site Randomization, Group III Single Site Randomization, Group III: Bilateral Site Randomization |
Primary outcome
1.To determine the efficacy of TCT in improving the appearance of post-surgical scars following oral supplementation 2.To determine the efficacy of TCT in improving the appearance of post-surgical scars following topical application
Time frame: 4 weeks prior to surgery and 12 weeks post surgery.
Results and safety
The study was stopped early (reason given: The PI moved to another Institution). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2021.
Related trials for Scar
Recruiting
A Study Assessing Arrhythmia Mapping With a Multi-Electrode Mapping Catheter
Scar-related Atrial Tachycardia, Persistent Atrial Fibrillation
Active, not recruitingPhase 1/2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
Recruiting
Clinical Impact of Uterine Repair During Cesarean Section With Barbed Suture on the Incidence of Isthmocele
Isthmocele, Cesarean Scar Defect
RecruitingPhase 2
Tirzepatide for Treatment of CCCA
Central Centrifugal Cicatricial Alopecia (CCCA)
Recruiting
Surgical Outcomes of Simple Interrupted Versus Running Epidermal Sutures in Full-thickness Skin Graft Placement
Skin Graft Scar
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chandan K Sen, PhD principal investigator
Ohio State University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Natural Vitamin E Tocotrienol supplement (TCT) and Natural Vitamin E Tocotrienol Cream (TCT) in people with Scar, run by Chandan K Sen at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 18 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: The PI moved to another Institution). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
1.To determine the efficacy of TCT in improving the appearance of post-surgical scars following oral supplementation 2.To determine the efficacy of TCT in improving the appearance of post-surgical scars following topical application (time frame: 4 weeks prior to surgery and 12 weeks post surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2021.